A Phase 2 interventional study of nab-Paclitaxel and Gemcitabine in Pancreatic Neoplasms, sponsored by Celgene. Completed at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-20.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.
Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 30th largest by enrollment, is one of 17 that started in 2015, is one of 69 in phase 2, and was the 35th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 87 · Phase 3 8 · Phase 4 2
First in 2006; this study’s year is marked. 17 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 47 across the 130 interventional studies. Of the 70 that completed or were terminated, 27 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb: 3 open now, 5 under way, 1 of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2015, is one of 5 in phase 2, and was the 11th registered.
Bristol-Myers Squibb’s Pancreatic Neoplasms studies by the year they started, since 2005.
14 of the studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02207465Abramson Cancer Center at Penn MedicineA Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer | 2026-12 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 27 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.
This is an international, non-randomized, open-label, multi-center, Phase 2 study in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. All subjects will be treated with nab-paclitaxel plus gemcitabine for 6 cycles followed by an Investigator's Choice of continuation of treatment with nab-paclitaxel plus gemcitabine, chemoradiation therapy, or surgery.
Safety assessments by laboratory testing and physical exams will be conducted through-out the study.
Efficacy assessments by physical exam will be preformed through-out the study and tumor imaging will be conducted approximately every 2 months.
Subjects will be considered active study participants from enrollment up to, but not including, survival follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No prior anticancer therapy for pancreatic cancer
•≥ 18 years of age with a performance status of 0 or 1•Adequate complete blood counts, hepatic function, and renal function
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject. * Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR * Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR * Surgical intervention
Drug: nab-Paclitaxel · Drug: Gemcitabine · Drug: Chemoradiation · Drug: Capecitabine · Procedure: Surgery
Also known as: Abraxane
Also known as: Gemzar
Surgical intervention
Kaplan-Meier Estimates for Time to Treatment Failure (TTF)
TTF was defined as the time after the first dose of study therapy to discontinuation of study therapy due to disease progression, death by any cause, or the start of a new non-protocol-defined anticancer therapy/surgery. If a participant does not progress, die or start a new non-protocol-defined anticancer therapy, the participant was censored on the last tumor assessment date. Tumor evaluations of CT or MRI scans were assessed by the investigative sites and response determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. The definition for progressive disease (PD) was \>= 20% increase in the sum of diameters of target lesions from nadir, and the sum showed an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval (CI) of TTF were estimated using the method of Brookmeyer and Crowley.
Time frame: Day 1 of study treatment up to 28.75 months; (maximum time for the last tumor assessment)
Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1
DCR was defined as the percentage of participants with a CR or PR or SD from of date of first treatment to 16 weeks. Tumor assessments after start of non-protocol-defined anticancer therapy were excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. * SD: neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method.
Time frame: Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks
Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1
ORR was defined as the percentage of participants that achieved a combined incidence of complete (CR) and partial response (PR) using RECIST 1.1 guidelines as assessed by the investigator. Assessments after new non-protocol-defined anticancer therapy are excluded. For participants who had resectable surgery in Investigator Choice period, assessments after surgical intervention are excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method
Time frame: Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks
Kaplan-Meier Estimate of Progression-Free Survival (PFS)
Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free. The definition for progressive disease (PD) was at least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval of PFS were estimated using the method of Brookmeyer and Crowley.
Time frame: Day 1 of study treatment up to 28.75 months (maximum time for the last tumor assessment)
Kaplan-Meier Estimates for Overall Survival (OS)
Overall survival was defined as the time from the date of first dose of study therapy to the date of death (by any cause). Participants who were alive at the end of study or clinical data cut were censored on the last known time that the participant was alive or the clinical cutoff date, whichever was earlier. Median and its 90% confidence interval of OS were estimated using the method of Brookmeyer and Crowley
Time frame: Day 1 of study treatment up to 31.34 months (maximum time for survival follow-up)
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Global Health Status and 5 Functioning Scales
The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 - 100 scale. In the Global Health Status and 5 functional scales, 0 = worst possible quality of life/health status and 100 = best possible quality of life/health status. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 increase from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 decrease from baseline
Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Symptom Scales and Single Symptom Items
The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 to 100 scale. In the symptom scales and single symptom items, 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 decrease from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 increase from baseline
Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Six Summary Scales
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. All reported measures are transformed to a 0 to 100 scale. Six summary scales reported are: - Pancreatic Pain - Digestive Symptoms - Altered Bowel Habits - Hepatic Scale - Body Image - Sexuality Scores of 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation
Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Satisfaction With Health Care Scale
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The summary scale for Satisfaction with Health Care is reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = not satisfied, worst possible health state and 100 = extremely satisfied, best possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID increase from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID decrease from baseline MID = half the baseline standard deviation
Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): 10 Individual Item Scores
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The 10 individual item scores are reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = best possible health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation
Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).
Time frame: Day 1 of study drug up to end of the study; up to 31.3 months
| Milestone | Nab-Paclitaxel Plus Gemcitabine | Investigator Choice |
|---|---|---|
| Started | 107 | 0 |
| Completed | 62 | 0 |
| Not completed | 45 | 0 |
| Withdrew: Enrolled but not treated | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 22 | 0 |
| Withdrew: Progressive disease | 8 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Noncompliance with study drug | 1 | 0 |
| Withdrew: Physician decision | 4 | 0 |
| Withdrew: Symptomatic deterioration | 2 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Other | 1 | 0 |
| Milestone | Nab-Paclitaxel Plus Gemcitabine | Investigator Choice |
|---|---|---|
| Started | 0 | 47 |
| Completed | 0 | 37 |
| Not completed | 0 | 10 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Progressive disease | 0 | 3 |
| Withdrew: Noncompliance with study drug | 0 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Unresectable surgery | 0 | 1 |
TTF was defined as the time after the first dose of study therapy to discontinuation of study therapy due to disease progression, death by any cause, or the start of a new non-protocol-defined anticancer therapy/surgery. If a participant does not progress, die or start a new non-protocol-defined anticancer therapy, the participant was censored on the last tumor assessment date. Tumor evaluations of CT or MRI scans were assessed by the investigative sites and response determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. The definition for progressive disease (PD) was \>= 20% increase in the sum of diameters of target lesions from nadir, and the sum showed an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval (CI) of TTF were estimated using the method of Brookmeyer and Crowley.
| months | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Kaplan-Meier Estimates for Time to Treatment Failure (TTF) | 9.0 (7.26 to 10.05) |
DCR was defined as the percentage of participants with a CR or PR or SD from of date of first treatment to 16 weeks. Tumor assessments after start of non-protocol-defined anticancer therapy were excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. * SD: neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method.
| percentage of participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1 | 77.6 (70.3 to 83.5) |
ORR was defined as the percentage of participants that achieved a combined incidence of complete (CR) and partial response (PR) using RECIST 1.1 guidelines as assessed by the investigator. Assessments after new non-protocol-defined anticancer therapy are excluded. For participants who had resectable surgery in Investigator Choice period, assessments after surgical intervention are excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method
| percentage of participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1 | 39.3 (31.8 to 47.2) |
Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free. The definition for progressive disease (PD) was at least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval of PFS were estimated using the method of Brookmeyer and Crowley.
| months | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) | 10.9 (9.26 to 11.63) |
Overall survival was defined as the time from the date of first dose of study therapy to the date of death (by any cause). Participants who were alive at the end of study or clinical data cut were censored on the last known time that the participant was alive or the clinical cutoff date, whichever was earlier. Median and its 90% confidence interval of OS were estimated using the method of Brookmeyer and Crowley
| months | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Kaplan-Meier Estimates for Overall Survival (OS) | 18.8 (14.95 to 24.02) |
The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 - 100 scale. In the Global Health Status and 5 functional scales, 0 = worst possible quality of life/health status and 100 = best possible quality of life/health status. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 increase from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 decrease from baseline
| Participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Global Health Status: Improved | 43 |
| Global Health Status: Stable | 34 |
| Global Health Status: Worsened | 18 |
| Physical Functioning Scale: Improved | 20 |
| Physical Functioning Scale: Stable | 66 |
| Physical Functioning Scale: Worsened | 9 |
| Role Functioning Scale: Improved | 36 |
| Role Functioning Scale: Stable | 46 |
| Role Functioning Scale: Worsened | 13 |
| Emotional Functioning Scale: Improved | 50 |
| Emotional Functioning Scale: Stable | 40 |
| Emotional Functioning Scale: Worsened | 5 |
| Cognitive Functioning Scale: Improved | 33 |
| Cognitive Functioning Scale: Stable | 51 |
| Cognitive Functioning Scale: Worsened | 11 |
| Social Functioning Scale: Improved | 38 |
| Social Functioning Scale: Stable | 43 |
| Social Functioning Scale: Worsened | 14 |
The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 to 100 scale. In the symptom scales and single symptom items, 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 decrease from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 increase from baseline
| Participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Symptom Scale-Fatigue: Improved | 46 |
| Symptom Scale-Fatigue: Stable | 24 |
| Symptom Scale-Fatigue: Worsened | 25 |
| Scale-Nausea+Vomiting: Improved | 29 |
| Scale-Nausea+Vomiting: Stable | 64 |
| Scale-Nausea+Vomiting: Worsened | 2 |
| Symptom Scale-Pain: Improved | 62 |
| Symptom Scale-Pain: Stable | 29 |
| Symptom Scale-Pain: Worsened | 4 |
| Symptom - Dyspnoea: Improved | 12 |
| Symptom - Dyspnoea: Stable | 74 |
| Symptom - Dyspnoea: Worsened | 9 |
| Symptom - Insomnia: Improved | 53 |
| Symptom - Insomnia: Stable | 35 |
| Symptom - Insomnia: Worsened | 7 |
| Symptom - Appetite loss: Improved | 48 |
| Symptom - Appetite loss: Stable | 39 |
| Symptom - Appetite loss: Worsened | 8 |
| Symptom - Constipation: Improved | 46 |
| Symptom - Constipation: Stable | 45 |
| Symptom - Constipation: Worsened | 4 |
| Symptom - Diarrhoea: Improved | 18 |
| Symptom - Diarrhoea: Stable | 69 |
| Symptom - Diarrhoea: Worsened | 8 |
| Symptom - Financial difficulties: Improved | 17 |
| Symptom - Financial difficulties: stable: | 74 |
| Symptom - Financial difficulties: Worsened | 4 |
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. All reported measures are transformed to a 0 to 100 scale. Six summary scales reported are: - Pancreatic Pain - Digestive Symptoms - Altered Bowel Habits - Hepatic Scale - Body Image - Sexuality Scores of 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation
| Participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Pancreatic Pain Scale: Improved | 62 |
| Pancreatic Pain Scale: Stable | 33 |
| Pancreatic Pain Scale: Worsened | 0 |
| Digestive Symptom Scale: Improved | 49 |
| Digestive Symptom Scale: Stable | 36 |
| Digestive Symptom Scale: Worsened | 10 |
| Altered Bowel Habits Scale: Improved | 28 |
| Altered Bowel Habits Scale: Stable | 53 |
| Altered Bowel Habits Scale: Worsened | 14 |
| Hepatic Scale: Improved | 25 |
| Hepatic Scale: Stable | 66 |
| Hepatic Scale: Worsened | 4 |
| Body Image Scale: Improved | 22 |
| Body Image Scale: Stable | 50 |
| Body Image Scale: Worsened | 23 |
| Sexuality Scale: Improved | 31 |
| Sexuality Scale: Stable | 51 |
| Sexuality Scale: Worsened | 13 |
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The summary scale for Satisfaction with Health Care is reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = not satisfied, worst possible health state and 100 = extremely satisfied, best possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID increase from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID decrease from baseline MID = half the baseline standard deviation
| Participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Satisfaction with Health Care Scale: Improved | 42 |
| Satisfaction with Health Care Scale: Stable | 40 |
| Satisfaction with Health Care Scale: Worsened | 13 |
The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The 10 individual item scores are reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = best possible health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation
| Participants | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Abdominal Bloating: Improved | 50 |
| Abdominal Bloating: Stable | 42 |
| Abdominal Bloating: Worsened | 3 |
| Taste Changes: Improved | 20 |
| Taste Changes: Stable | 54 |
| Taste Changes: Worsened | 21 |
| Indigestion: Improved | 41 |
| Indigestion: Stable | 47 |
| Indigestion: Worsened | 7 |
| Flatulence: Improved | 47 |
| Flatulence: Stable | 37 |
| Flatulence: Worsened | 11 |
| Weight Loss: Improved | 36 |
| Weight Loss: Stable | 56 |
| Weight Loss: Worsened | 3 |
| Limb Weakness: Improved | 22 |
| Limb Weakness: Stable | 55 |
| Limb Weakness: Worsened | 18 |
| Dry Mouth: Improved | 37 |
| Dry Mouth: Stable | 45 |
| Dry Mouth: Worsened | 13 |
| Treatment Side-Effects: Improved | 8 |
| Treatment Side-Effects: Stable | 48 |
| Treatment Side-Effects: Worsened | 39 |
| Worry About Future Health: Improved | 42 |
| Worry About Future Health: Stable | 45 |
| Worry About Future Health: Worsened | 8 |
| Limits on Activity Planning: Improved | 42 |
| Limits on Activity Planning: Stable | 42 |
| Limits on Activity Planning: Worsened | 11 |
TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).
| Participants | Nab-Paclitaxel Plus Gemcitabine (Induction Period) | Nab-Paclitaxel Plus Gemcitabine (Overall) |
|---|---|---|
| >= 1 TEAE | 105 | 105 |
| >=1 related TEAE | 102 | 103 |
| >=1 TEAE of severity grade 3 or higher | 85 | 90 |
| >=1 related TEAE of severity grade 3 or higher | 72 | 75 |
| >=1 serious TEAE | 38 | 39 |
| >= 1 related serious TEAE | 14 | 14 |
| >=1 TEAE leading to discontinuation of IP | 25 | 28 |
| >=1 related TEAE leading to discontinuation of IP | 15 | 18 |
| >=1 TEAE leading to dose reduction of IP | 69 | 72 |
| >=1 related TEAE leading to dose reduction of IP | 68 | 71 |
| >=1 TEAE leading to interruption of IP | 66 | 68 |
| >=1 related TEAE leading to interruption of IP | 48 | 50 |
| >= TEAE leading to death | 2 | 2 |
| >=1 related TEAE leading to death | 0 | 0 |
Collected over Day 1 of study drug up to end of the study; up to 31.3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nab-Paclitaxel Plus Gemcitabine (Induction Period) | 42/106 (39.6%) | 38/106 (35.8%) | 104/106 (98.1%) |
| Nab-Paclitaxel Plus Gemcitabine (Overall) | 67/106 (63.2%) | 39/106 (36.8%) | 104/106 (98.1%) |
| Event | Nab-Paclitaxel Plus Gemcitabine (Induction Period) | Nab-Paclitaxel Plus Gemcitabine (Overall) |
|---|---|---|
| PyrexiaGeneral disorders | 5/106 | 5/106 |
| PneumoniaInfections and infestations | 5/106 | 5/106 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/106 | 3/106 |
| Atrial fibrillationCardiac disorders | 2/106 | 2/106 |
| Abdominal painGastrointestinal disorders | 2/106 | 2/106 |
| CellulitisInfections and infestations | 2/106 | 2/106 |
| Neutropenic sepsisInfections and infestations | 2/106 | 2/106 |
| SepsisInfections and infestations | 2/106 | 2/106 |
| Blood bilirubin increasedInvestigations | 1/106 | 1/106 |
| DehydrationMetabolism and nutrition disorders | 1/106 | 1/106 |
| Event | Nab-Paclitaxel Plus Gemcitabine (Induction Period) | Nab-Paclitaxel Plus Gemcitabine (Overall) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 57/106 | 57/106 |
| FatigueGeneral disorders | 53/106 | 53/106 |
| AnaemiaBlood and lymphatic system disorders | 49/106 | 49/106 |
| DiarrhoeaGastrointestinal disorders | 48/106 | 48/106 |
| NauseaGastrointestinal disorders | 46/106 | 47/106 |
| Oedema peripheralGeneral disorders | 45/106 | 47/106 |
| Decreased appetiteMetabolism and nutrition disorders | 46/106 | 46/106 |
| NeutropeniaBlood and lymphatic system disorders | 44/106 | 45/106 |
| PyrexiaGeneral disorders | 39/106 | 40/106 |
| AstheniaGeneral disorders | 36/106 | 36/106 |
Intent-to-treat (ITT) population at start of Induction
| Age, Continuous(years) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Median | 65.0 (42 to 85) |
| Age, Customized(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| <65 years | 44 |
| >=65 - 75 years | 50 |
| >75 years | 13 |
| Sex: Female, Male(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Female | 59 |
| Male | 48 |
| Ethnicity (NIH/OMB)(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 78 |
| Unknown or Not Reported | 28 |
| Race (NIH/OMB)(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 72 |
| More than one race | 0 |
| Unknown or Not Reported | 30 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Grade 0 | 50 |
| Grade 1 | 57 |
| Grade 2 | 0 |
| Grade 3 | 0 |
| Grade 4 | 0 |
| Physician Assessment of Peripheral Neuropathy(Participants) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Grade 0 | 101 |
| Grade 1 | 6 |
| Grade 2 | 0 |
| Grade 3 | 0 |
| Grade 4 | 0 |
| Baseline Albumin(g/L) | Nab-Paclitaxel Plus Gemcitabine |
|---|---|
| Median | 39.0 (28 to 50) |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in Nov 2017, 31 months.
Results were first posted in Jan 2019, 1 year 1 month after primary completion.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 31 months is below that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine